This paper is only available as a PDF. To read, Please Download here.
Abstract
When interleukin-2 alone or in combination with lymphokine-activated killer (LAK)
cells is administered to patients with cancer, peripheral or local eosinophilia is
frequently seen. To evaluate the role of eosinophils in this setting, we studied the
functional changes of human eosinophils induced by the supernatant of LAK cell cultures.
The chemotactic activity, change in chemiluminescence, superoxide production, expression
of leukocyte integrins (CD11/CD18 family), and adherent activity to plastic dishes
were investigated after stimulation of eosinophils with LAK cell culture supernatant.
The chemotactic activity of eosinophils in the supernatant of LAK cell cultures was
increased significantly, and this activity was chemotactic rather than chemokinetic
by checkerboard analysis. Both chemiluminescence and superoxide production of stimulated
eosinophils increased significantly compared with resting. In addition, eosinophil-adherent
activity to plastic dishes was also increased. Among leukocyte integrins, CD11b expression
on stimulated eosinophils increased. Moreover, eosinophil antibody-dependent cellular
cytotoxity against Raji cells was enhanced after stimulation with the supernatant
of LAK cell cultures. These results suggest that the eosinophils activated by LAK
cells may play an important role in the antitumor effect of interleukin-2/LAK cell
therapy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med. 1985; 313: 1485-1492
- Constant-infusion interleukin-2 in adoptive immunotherapy of advanced cancer.N Engl J Med. 1987; 316: 898-905
- Immunotherapy of cancer using IL-2.Immunol Today. 1988; 9: 58-62
- Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells.J Immunol. 1989; 142: 2162-2167
- The appearance of hypodense eosinophils during interleukin-2 treatment.J Allergy Clin Immunol. 1990; 85: 557-566
- Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.J Immunol. 1987; 138: 4033-4041
- A comparison of eosinophil-activating factor (EAF) with other monokines and lymphokines.Eur J Immunol. 1986; 16: 1143-1149
- The regulation of human eosinophil function by cytokines.Immunol Today. 1987; 8: 380-385
- An eosinophil chemotactic factor in lymphokine-activated killer (LAK) cell supernatant [Abstract].in: Fed Proc. 4. 1990: 1945
- A new method for the purification of human eosinophils and neutrophils and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.J Immunol. 1979; 122: 1228-1236
- The role of serum complement in chemotaxis of leukocytes in vitro.J Exp Med. 1965; 122: 327-347
- Amsakis and eosinophils I. Detection of a soluble factor selectively chemotactic for eosinophils in the extract from Anisakis larvae.J Immunol. 1978; 120: 745-749
- Studies in experimental eosinophilia. V. Eosinophils in lymph nodes of guinea pig following primary antigenic stimulation.Am J Pathol. 1963; 42: 529-547
- Recombinant human interleukin 5 is a selective eosinophil chemoattractant.Eur J Immunol. 1989; 19: 701-705
- Stimulation of neutrophils by tumor necrosis factor.J Immunol. 1986; 136: 4220-4225
- Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.J Clin Invest. 1986; 78: 1220-1228
- Enhanced adherence activity of OK432-induced peritoneal neutrophils to tumor cells correlates with their increased expression of CD11b/CD18.Clin Immunol Immunopathol. 1991; 59: 474-486
- Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes: involvement of oxidative and nonoxidative mechanisms.J Natl Cancer Inst. 1984; 73: 331-339
- Role of IL-5 in IL-2-induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2.J Immunol. 1990; 145: 873-877
- Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.Cancer Res. 1989; 49: 5469-5474
- Interleukin-2 enhances natural killing of normal monocytes.Cell Immunol. 1984; 84: 154-162
- Eosinophil-mediated mammalian tumor cell cytotoxity: role of the peroxidase system.J Immunol. 1980; 124: 1949-1953
- Mechanism of killing of newborn larvae of Trichinella spiralis by neutrophils and eosinophils: killing by generators of hydrogen peroxide in vitro.J Clin Invest. 1979; 64: 1558-1564
- Functional role of the α-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxity against schistosomes.J Immunol. 1987; 139: 2059-2065
- IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leukocyte integrin (CD11/CD18)-dependent manner.Immunology. 1990; 71: 258-265
- Recombinant human interleukin 5 is a selective activator of human eosinophil function.J Exp Med. 1988; 167: 219-224
- Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.J Clin Invest. 1988; 81: 1986-1992
- Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium.J Exp Med. 1990; 171: 2025-2041
- Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.in: Proc Natl Acad Sci USA. 83. 1986: 1055-1059
- Effects of IFN on human eosinophils in comparison with other cytokines: a novel class of eosinophil activators with delayed onset of action.J Immunol. 1990; 145: 2950-2958
- Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells.Cancer Res. 1988; 48: 5864-5867
- Induction of cytokinemRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.J Immunol. 1989; 143: 736-739
- Fcγ and CD11/CD18 receptor expression on normal density and low density human eosinophils.Immunology. 1990; 69: 264-270
- Eosinophil infiltration of human colonic carcinomas as a prognostic indicator.Cancer Res. 1983; 43: 2997-3000
- Malignant tumor and eosinophils. I. Prognotic significance in gastric cancer.Cancer. 1986; 58: 1321-1327
- Local responses in primary and secondary human lung cancers. II. Clinical correlations.Br J Cancer. 1979; 40: 410-416
- Tumor-associated eosinophilia: a review.J Clin Pathol. 1981; 34: 1343-1348
- Local eosinophilia in stroma of tumors related to prognosis.Neoplasma. 1984; 31: 323-326
Article info
Publication history
Accepted:
October 30,
1991
Identification
Copyright
© 1993 Published by Elsevier Inc.
